Featured Articles From The Current Issue
SPECIAL FEATURE - Platform Technologies - Derisking & Transforming Drug Development
Contributor Cindy H. Dubin, in this second annual report, speaks with several exciting and innovative companies whose platform technologies are transforming drug development.


>>> See All Cover Stories

Smruti P. Chaudhari, PhD, and Anshul Gupte, PhD, successfully reformulated tablets using the potassium-salt form of Compound XY without adding any new excipient. Through the reformulation, they also resolved earlier issues faced during tablet compression.
Degenhard Marx, PhD, and Matthias Birkhoff highlight their company’s Ophthalmic Squeeze Dispenser (OSD), a multi-dose dropper that relies solely on mechanical measures to prevent microbial contamination of the bottle content.
Jeff Galvin believes as the pace of gene and cell therapies accelerates over this next decade, potential cures for chronic diseases, cancer cures, and autosomal defect cures will result, and the efficacy of new therapeutics may move as much as $500 billion from traditional pharmaceuticals to gene technologies.
Horst Koller and John A. Merhige, MEM, say the advantages of a Staked Needle Pre-Filled Syringe are clear and well documented, but significant risks remain. A new alternative is now available that addresses the known challenges and adds critical usability and safety features while preserving existing components and processes.
Jason M. LePree, RPh, PhD, reviews the causes of poor bioavailability for drugs and provides an introduction to lipid-based drug delivery systems, and how the formulation approach can be used to overcome impediments to good bioavailability of therapeutic actives.
Dr. Mark Mitchnick, CEO of Particle Sciences and CMO of Lubrizol, discusses the rise of complex drug products, the capabilities needed to develop and manufacture these products, and the company's expansion in this area.
Bas van Buijtenen, President of the Aptar Pharma Injectable Division, reviews the past 12 months and assesses what will drive the market in the future.
Contributor Cindy H. Dubin reports on a segment of the drug delivery industry that will see its market revenue double in just 5 years in response to a growing need to deliver highly viscous, high-volume drugs.
Torsten Maschke, CEO of Datwyler Sealing Solutions, speaks about the opportunities and challenges the current healthcare industry poses and how they are met by Datwyler’s strategy and products.
Jeannie Joughin, PhD, asks what does a pharmaceutical company do when everyone wants more effective new therapies but no one – including third-party payers – wants to pay the price for their development? De-risk the drug development process, in every possible way.
Detlev Haack, PhD, and Martin Koeberle, PhD, says an industry-wide focus on the design of packaging that can protect user-friendly dosage forms, as well as improve patient compliance and fit into modern consumers’ lifestyles, has resulted in a wide range of primary and secondary packaging solutions.
Tim Leaver explains how his company has developed a proprietary technology for the rapid development of nanoparticles and seamless scale-up for clinical studies and commercial production, and how it is transforming the development and manufacturing of a range of nanoparticle formulations from a hit-and-miss affair to a standardized process, accelerating novel nanomedicines from the bench to the clinic.
Exclusive Online Content
Vetter to Expand its Secondary Packaging Service Capacity to Meet Rising Demands Vetter to Expand its Secondary Packaging Service Capacity to Meet Rising Demands
Vetter, a global leader in prefilled drug delivery systems and an expert in complex packaging projects, recently announced a major expansion of its secondary packaging capacities as a response to rising customer needs and market demands for complex packaging solutions.

Arcturus Therapeutics Announces Strategic Collaboration With J&J Innovation to Discover & Develop RNA MedicinesArcturus Therapeutics Announces Strategic Collaboration With J&J Innovation to Discover & Develop RNA Medicines
Arcturus Therapeutics, Inc. recently announced it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The two companies will work together to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform.

White Paper: Establishing cGMP Manufacturing Capability for Phase 1 Sterile, Dispersed, Injectable Dosage FormsWhite Paper: Establishing cGMP Manufacturing Capability for Phase 1 Sterile, Dispersed, Injectable Dosage Forms
As a product transitions from pre-clinical development to a clinical development phase, the manufacturing process takes on a much greater role in the overall success of the project.........

AMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis & Toxicology Risk AssessmentAMRI Launches Stand-Alone Service; Expanding Solutions for Impurity Analysis & Toxicology Risk Assessment
AMRI, a global contract research, development and manufacturing organization that partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will now be offering its impurity solutions as a stand-alone service.

Cambrex Invests in Generic API Development & Manufacturing Capabilities at its Milan SiteCambrex Invests in Generic API Development & Manufacturing Capabilities at its Milan Site
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), recently announced that it has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy.

Aptar Pharma Showcase its Premium Injectables Portfolio Aptar Pharma Showcase its Premium Injectables Portfolio
Aptar Pharma, a leading drug delivery systems provider, will showcase the latest developments in its Premium injectables portfolio when it exhibits at Parenteral Drug Association’s (PDA) Universe of Pre-filled Syringes and Injection Devices in November.

CordenPharma Acquires Pfizer API Manufacturing Facility in Boulder, COCordenPharma Acquires Pfizer API Manufacturing Facility in Boulder, CO
CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO), has entered into definite agreements to acquire the former Hospira Boulder (Colorado) high containment API site from Pfizer, Inc. The closing of the transaction is anticipated to occur in November 2017.

KemPharm & Genco Sciences Announce Technology Licensing Agreement KemPharm & Genco Sciences Announce Technology Licensing Agreement
KemPharm, Inc., a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, recently announced it has entered into a technology licensing and assignment agreement with Genco Sciences, LLC (Genco).

Achieve Life Science Announces Advancement of Cytisine Clinical Development Program Achieve Life Science Announces Advancement of Cytisine Clinical Development Program
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, recently announced the commencement of a multi-dose study to evaluate both PK and PD characteristics of cytisine.

Amgen-Backed Immatics Lands $58 Million to Develop T-Cell Receptor-Based Immunotherapies Amgen-Backed Immatics Lands $58 Million to Develop T-Cell Receptor-Based Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, recently announced the completion of its Series E financing, raising $58 million.
Market News & Trends





















- SHL


Click here to see the showcases


BIO Investor Forum
October 17-18, 2017
The Westin St. Francis, San Francisco, CA US
 
Partnership Opportunities in Drug Delivery (PODD)
October 19-20
Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Vienna, Austria

AAPS
November 12-17
San Diego, CA

Pre-Filled Syringes Europe
January 17-18, 2018
Copthorne Tara Hotel, London UK

Drug Delivery Partnerships
January 22-24 Palm Beach, FL

3rd Annual Drug Development Networking Summit
March 8, 2018  Hilton Hotel Parsippany NJ
 
PDA Annual Meeting
March 19-21 Orlando, FL
 
CPhI North America
April 24-26 Philadelphia, PA 
 
INTERPHEX
April 17-19 New York City
 
RDD (Respiratory Drug Delivery)
April 22-26 Tucson, AZ
 
BIO 2018
June 4-7 Boston, MA
 
Controlled Release Society Meeting
July 23-25 New York City
 
Universe of Prefilled Syringes & Injection Devices
October 8-9 Orlando, FL
 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions